CER-T Cell Platform
Hematologic Malignancies
Key Facts
About CERo Therapeutics
CERo Therapeutics is developing next-generation cell therapies designed to overcome limitations of current immunotherapies by creating multifunctional T cells. Its proprietary CER platform engineers T cells to recognize 'Eat Me' signals on tumors, enabling them to engulf cancer cells, kill them directly, and present tumor antigens to stimulate a broader, secondary immune response. This integrated approach aims to enhance curative potential and safety, positioning CERo in the competitive but high-potential field of advanced cell therapies for oncology.
View full company profileAbout CERo Therapeutics
CERo Therapeutics is developing next-generation cell therapies designed to overcome limitations of current immunotherapies by creating multifunctional T cells. Its proprietary CER platform engineers T cells to recognize 'Eat Me' signals on tumors, enabling them to engulf cancer cells, kill them directly, and present tumor antigens to stimulate a broader, secondary immune response. This integrated approach aims to enhance curative potential and safety, positioning CERo in the competitive but high-potential field of advanced cell therapies for oncology.
View full company profileTherapeutic Areas
Other Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Hematologic Malignancies) | AbelZeta Pharma | Clinical |
| PredicineHEME™ | Predicine | Commercial |
| Orca-T | Bristol Myers Squibb | Phase 3 |
| NK‑Thera | Vectorite Biomedical | Phase 1/2 |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Development |
| DARIC-NK Program | Coeptis Therapeutics | Preclinical |
| TSC-102-A01 | TScan Therapeutics | Preclinical |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1/2 |